EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study

Hiroshi Kikuchi iD, Takahiro Osawa iD, Yuto Matsushita iD, Takahiro Kojima iD, Tomokazu Sazuka, Shingo Hatakeyama, Keisuke Goto, Kazuyuki Numakura iD, Kazutoshi Yamana, Shuya Kandori iD, Kosuke Ueda iD, Hajime Tanaka und 10 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf018 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hiroshi Kikuchi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo 060-8638, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Axitinib, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To validate multiple prognostic models in metastatic renal cell carcinoma patients who received second-line axitinib following first-line nivolumab plus ipilimumab therapy.

Methods

Five prognostic models (ACL, albumin, C-reactive protein, and lactate dehydrogenase; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC, Memorial Sloan Kettering Cancer Center; ATP, axitinib treatment prediction; JMRC, Japanese metastatic renal cancer) to predict overall survival (OS) were validated and compared using data from 86 metastatic renal cell carcinoma patients who received second-line axitinib therapy following first-line nivolumab plus ipilimumab therapy at 34 hospitals affiliated with the Japan Urologic Oncology Group.

Results

The Karnofsky performance status, time from initial diagnosis to first-line therapy, and hemoglobin, platelet, albumin, and C-reactive protein levels correlated with OS in univariate Cox regression analyses. Among these factors, only albumin had a significant impact on OS in the multivariate analysis. The integrated area under the curve (AUC) of the ACL, IMDC, MSKCC, ATP, and JMRC models were 0.78, 0.76, 0.76, 0.69, and 0.70, respectively. The ACL model showed a higher value than the others in the time-dependent AUC.

Conclusions

The accuracy of the five prognostic models (ACL, IMDC, MSKCC, ATP, and JMRC) created in the pre–immuno-oncology (IO) treatment cohort was maintained in the second-line axitinib group after nivolumab plus ipilimumab therapy. The ACL model demonstrated moderate accuracy in predicting OS with the fewest number of clinical variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAxitinibKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansNivolumabMaleRetrospective StudiesFemaleIpilimumabMiddle AgedAgedPrognosisAged, 80 and overAdultJapanEast Asian People

Stichwörter der Autor:innen

axitinibrenal cell carcinomasystemic therapy

Substanzen

NivolumabIpilimumabAxitinib

Autor:innen und Institutionen

  • Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo 060-8638, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Japan.
  • Department of Urology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa Ward, Nagoya 464-8681, Japan.
  • Department of Urology, Graduate School of Medicine Chiba University, 1-8-1 Inohana, chuo-ku, Chiba 260-8670, Japan.
  • Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.
  • Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.

ORCID-Profile: Hiroshi Kikuchi, Takahiro Osawa, Yuto Matsushita, Takahiro Kojima, Kazuyuki Numakura, Shuya Kandori, Kosuke Ueda, Takahiro Kimura

Zitieren

APA

Kikuchi, H., Osawa, T., Matsushita, Y., Kojima, T., Sazuka, T., Hatakeyama, S., Goto, K., Numakura, K., Yamana, K., Kandori, S., Ueda, K., Tanaka, H., Kurahashi, T., Bando, Y., Kimura, T., Nishiyama, N., Kato, T., Hara, H., Ito, Y., …, & Shinohara, N. (2025). Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf018

Vancouver

Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, et al. Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf018

BibTeX
@article{Kikuchi2025,
  author = {Kikuchi, Hiroshi and Osawa, Takahiro and Matsushita, Yuto and Kojima, Takahiro and Sazuka, Tomokazu and Hatakeyama, Shingo and Goto, Keisuke and Numakura, Kazuyuki and Yamana, Kazutoshi and Kandori, Shuya and Ueda, Kosuke and Tanaka, Hajime and Kurahashi, Toshifumi and Bando, Yukari and Kimura, Takahiro and Nishiyama, Naotaka and Kato, Takuma and Hara, Hiroaki and Ito, Yoichi and Kitamura, Hiroshi and Miyake, Hideaki and Shinohara, Nobuo},
  title = {Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf018}
}
Kostenlos starten →